RDHL company alerts

RDHL updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for RDHL. Subscribe to RDHL alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Subscribe for RDHL alerts View companies

Official-source feed

Recent RDHL alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

Company newsOfficial company sourceNov 2, 2026

Two labs report in vitro MAP-killing results for RHB-204

RedHill reported that two sets of in vitro studies confirmed RHB-204's capability to kill Mycobacterium avium subspecies paratuberculosis (MAP) and showed MAP-killing comparable to RHB-104 in long-term intracellular culture and spot and phage assays. The company described RHB-204, a fixed-dose oral formulation of clarithromycin, rifabutin and clofazimine, as Phase 2-ready and said it is pursuing partnerships, collaborations and innovation development grant applications. The release cited RHB-104's prior Phase 3...

Read source-backed brief

Debt offeringSEC filingOct 15, 2026

RedHill Biopharma files prospectus supplement to increase ATM offering with H.C. Wainwright

On October 13, 2026, RedHill Biopharma Ltd. filed a prospectus supplement to increase the maximum aggregate offering amount of American Depositary Shares (each representing 10,000 ordinary shares) that may be issued and sold from time to time under the At The Market Offering Agreement with H.C. Wainwright & Co., LLC dated February 3, 2025. Each Placement ADS represents 10,000 ordinary shares, no par value. The placement ADSs are offered under the Company's Form F-3 registration statement (No. 333-281417), and th...

Read source-backed brief